A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Clinical trial NCT06383767 · RECRUITING

Trial details

NCT number: NCT06383767
Sponsor: Qilu Pharmaceutical Co., Ltd.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Metastatic Breast Cancer

Start date: 2024-07-11
Primary completion: 2027-06-30
Enrollment: 378

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.